Effects of angiotensin II antagonists in comparison to ACE inhibitors in patients with heart failure due to systolic left ventricular dysfunction

Heart Failure Reviews

Volumn 3, Issue 3, 1999, Pages 221-232

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE CONTRACTION; HUMAN; MORBIDITY; MORTALITY; REVIEW;

EID: 0032804297     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009717702189     Document Type: Review

References (115)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Hypertension 1983;5 (Suppl III):139.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-301.
5. Cooper WD, Sheldon D, Brown D, et al. Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice. J R Coll Gen Pract 1987;37 :346.
6. Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 1987;24:343.
7. Garge R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA 1995;18: 1450-1455.
8. Sueta CA, Metts A, Griggs TR, Borders VC, Simpson RJ Jr. ACE-I use and LV function in the elderly admitted with heart failure: gender differences. J Am Coll Cardiol 1997;29: 324A.
9. Scott Levin, PDDA, 1996.
10. Timmermans P, Benfield P, Chiu AT, et al. Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5: 221S.
11. Waeber B, Burnier M, Nussberger J, Brunner HR. Experience with angiotensin II antagonists in hypertensive patients. Clin Exp Pharmacol Physiol Suppl 1996;3:S142-S146.
12. Ravid D, Lishner M, Lang R, Ravid M. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994;34:1116.
13. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, Mizuno T, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204-2211.
14. Thurmann PA. Angiotensin II antagonism and the heart-valsartan in left ventricular hypertrophy. Presented at the 8th European Meeting on Hypertension, Milan, Italy, June 17, 1997.
15. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease; the Framingham Study. Ann Intern Med 1970;72:813-822.
16. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. The losartan intervention for endpoint reduction (LIFE) in hypertension study rationale, design, and methods. Am J Hypertens 1997; 10:705-713.
17. Sharma D, Briggs B, Rucinska E, et al. Losartan in heart failure overview: a meta-analysis of observed mortality data from all controlled, double-blind, multiple-dose studies, in press.
18. Gottlieb S, Dickstein K, Fleck E, Kostis J, Levine TB, Le-Jemtel T, KeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88(Pt I): 1602-1609.
19. Dickstein K, Gottlief S, Fleck E, Kostis J, Levine B, Dekock M, Lejerntel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994;12(2):31-35.
20. Dickstein K, Chang P, Willenheimer R, Hauso ST, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995:26:438-445.
21. Klinger G, Jaramillo N, Ikram H, et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure (abstract). J Am Coll Cardiol 1997:29 (Suppl A):205A.
22. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Change PI, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
23. Cohn JN, Baruch L, and the VALHeFT Investigators. Additive haemodynamic and hormonal effects of valsartan and ACE inhibition: rationale for VALHeFT (abstract 25). 1st International Symposium on Angiotensin II Antagonism, London, United Kingdom, September 1997.
24. Pahor M, Gambassi G, Camfonin P. Antiarrhythmic effects of ACE inhibitors: a matter of faith or reality? Cardiovasc Res 1994;28:173-182.
25. Binkley PF, Nunziata E, Leier C. Selective AT-1 blockade with losartan does not restore autonomie balance in patients with heart failure (abstract 282). 1st Annual Scientific Meeting, Heart Failure Society of America, Baltimore, MD, September 1997.
26. Binkley PF, Nunziata E, Hatton P, Cody RJ. Angiotensin convertin enzyme inhibition does not restore diurnal variation of autonomie tone in heart failure (abstract 289). 1st Annual Scientific Meeting, Heart Failure Society of America, Baltimore, MD, September 1997.
27. Thomas GP, Ferrier GR, Howlett SE. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular and reperfusion. J Pharm Exp Ther 1996:278:1090-1097.
28. Hirsh AT, Dzau VT. Tissue renin-angiotensin systems; insights regarding the pathophysiology of heart failure. Heart Failure 1991;7:59-78.
29. Benjamin N, Collier JG, Webb DJ. Angiotensin II augments sympathetically induced vasoconstriction in man. Clin Sci 1988;75:337-340.
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
31. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new TREND? Circulation 1996;94:2403.
32. Zhang H, Garlichs CD, Schmeiber A, Damme U, Plotze K, Daniel WG. Angiotensin II induced Superoxide anion release is mediated by angiotensin type 1 receptor in human endothelial cells. Eur Heart J 1997;18 (Suppl):489.
33. Wilke A, Funck R. Rupp H, Brilla CG. Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 1996;91 (Suppl 2):79-84.
34. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;332:1561-1566.
35. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 1996;78: 880-892
36. Boadle MC, Hughes J, Roth RH. Angiotensin accelerates catecholamine biosynthesis in sympathetically innervated tissues. Nature 1969;222:987-988.
37. Timmermans PBMWM, Smith RD. A new class of therapeutic agents: the angiotensin II receptor antagonists. Cardiologia 1994;39 (Suppl 1):397-400.
38. Timermans PBMWM, Smith RD. The diversified pharmacology of angiotensin II receptor blockade. Blood Press 1996; (Suppl 2):53-61.
39. Yang HYT, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochemic Biophysic Acta 1970;214:374-376.
40. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens 1991;9:385-392.
41. Cachefeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. 1992;19:138-145.
42. Schror K. Converting enzyme inhibitors and the interaction between kinins and eicosanoids. J Cardiovasc Pharmacol 1990;15 (Suppl 6):S60-S90.
43. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Garere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomoto: dysfunction in patients with coronary artery disease: The TREND Study (Trial on Reversing Endothelial Dysfunction). Circulation 1996;94:258-265.
44. Zhange X, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95: 176-182.
45. Linz W, Scholkens BA. A specific BK2-bradykinin receptor antagonist HOE-140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1991;105:771-772.
46. Paratt JR, Begh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: brief review of the evidence. Can J Physiol Pharmacol 1995;73:837-842.
47. Linz W, Scholkens BA, Kaiser J, Just M, Bei-Yin Q, Albus U, Petry P. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formatin and bradykinin degradation with the converting-enzyme inhibitor ramipril. Cardiovasc Drugs Ther 1989;3:873-882.
48. Rajani V, Hussain Y, Bolk BS, deGuzman FQ, Montiaque RR, Lgic R, Rabito SF. Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins. Am J Cardiol 1997;80(3A):153-157.
49. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal of the bradykinin antagonists HOE-140, J Cardiovasc Pharmacol 1993;21:996-1103.
50. McDonald KM, Mock J. D'Aloia A, Parrish T, Hauer K. Francis G, Stilllman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-2048.
51. Holtz J. Pathophysiology of heart failure and the renin-angiotensin-system. Basic Res Cardiol 1993;88 (Suppl 1): 183-201.
52. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infraction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-719.
53. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
54. Milavetz J, Raya TE, Morkin E, Goldman S. Survival after large myocardial infarction in rats: comparison of ACE inhibition with captopril versus direct angiotensin II blockade with losartan. J Am Coll Cardiol 1995;221A.
55. Qing G, Garcia R. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol 1992;263:833-840.
56. Nishikimi T, Tani T, Ohmura T, Yamagishi H, Yanagi S, Yoshiyama M, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Angiotensin II type I receptor antagonist as well as angiotensin converting enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Jpn Circ J 1995;59:754-761.
57. Buser PT, Zhu P, Hornstein P, Allegrinin PR, Zaugg CE. Cardioprotection by the ATI-receptor blocker losartan is dependent on bradykinin receptor activation. J Am Coll Cardiol 1997;29:267A.
58. Duncan AM, Burrell LM, Kladis A, Campbell DJ. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 1996;28:746-754.
59. Kimura E, Hashimoto K, Furakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J 1973;85: 635-647.
60. Hashimoto K, Hirose M, Furukawa S, Hayakawa H, Kimura E. Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J 1977;18:679-689.
61. Marshall RJ, Purratt JR. The early consequences of myocardial ischaemia and their modification. J Physiol 1980;76:699-715.
62. Pitt B, Mason J, Conti CR, Coman RW. Activation of the plasma kallikrein system during myocardial ischaemia. Adv Exp Med Biol 1970;8:343-347.
63. Sicuteri F, Antonini FM, DelBianco PL, Franchi G, Curradi C. Pre-kallikrein and kallikrein inhibitor in plasma of patients affected by recent myocardial infarction. Adv Exp Med Biol 1972;21:445-449.
64. Hashimoto K, Hamamoto H, Honda Y, Hirose M, Furukawa S, Kimura E. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am Heart J 1978;95:619-626.
65. Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxation to bradykinin by angiotensin 1-converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992;71:137-144.
66. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997;39:287-324.
67. Rafflenbuhl W, Bassenge E, Lichtlen P. Konkurrenz zwishchen endothelabhangiger und nitroglycerin-induzierter koronarer vasodilitation. Z Kardiol 1989;78 (Suppl 2): 45-47.
68. Sudhir K, MacGregor JS, Gupta M, Barbant SD, Redberg R, Yock PG, Chatterjee K. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and doppler ultrasound studies. Circulation 1993;87:931-938.
69. Mantelli L, Amerini S, Ledda F. Bradykinin-induced vasodilation is changed to a vasoconstrictor response in vessels of aged normotensive and hypertensive rata. Inflamm Res 1995;44:70-73.
70. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Cln Invest 1993;92:2867-2871.
71. Takeishi Y, Atsumi H, Fujiwara S, Takahasi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-1089.
72. Urata H, Konshita A, Misono KS, Bumpus FM, Hussain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human chymase. J Biol Chem 1990;265:2348-2357.
73. Pouleur H, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction during enalapril therapy: relationship with neuro-hormonal reactivation. Circulation 1993;88:8-293.
74. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively now angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2:277-284.
75. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-227.
76. Dell-Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997;100:253-258.
77. Schieffer E, Hermann G, Muller B, Gunther R, Simon R, Studer R, Drexler. Expression of angiotensin II-forming enzymes in atherosclerotic human coronary arteries: selective upregulation in unstable angina. Eur Heart J 1996;17: 420.
78. Uehara Y, Kinoshita A, Nakayama S, Urata H, Noda K, Sasaguri M, Ideishi M, Tashiro T, Kimura M, Arakawa K. Significant positive correlation between chymase-like activity of the human internal mammary artery and serum cholesterol level (abstract). Circulation 1997;96 (Suppl):I-763.
79. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137.
80. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type I antagonists. Clin Exp Pharmacol Physiol Suppl 1996;3:S125-S131.
81. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-2520.
82. Barton M, Shaw S, Hscio LV, Luscher TF. Angiotensin IV increases circulating and tissue endothelin-1 in vivo and stimulate endothelin-1 release from human endothelial cells (abstract). Circulation 1997;96 (Suppl):I-113.
83. Vaughn D, personal communication.
84. Luscher T, personal communication.
85. Tanaka M, Ohnishi J, Ozawa Y, Sugimoto M, Usuki S, Naruse M, Murakami K, Miyazaki H. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun 1995;207:593-598.
86. Wiemer G, Scholkens BA, Wagner A, Heitsch H, Linz W. The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens 1993;11 (suppl5):S234-S235.
87. Olson SC, Dowds TA, Oeckler R, Burke-Wolin TM. Angiotensin II stimulation of nitric oxide synthase via the At2 receptor requires a tyrosine protein kinase (abstract). Circulation 1997;96 (Suppl):I-61.
88. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-269.
89. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tange SS. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;267:H844-H852.
90. Regitz-Zagrosek V, Friedel N, Schuler S, Heymann A, Hetzer R, Fleck E. Loss of myocardial angiotensin II receptors in end stage human heart failure. Circulation 1993;88 (Suppl):I-475.
91. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935.
92. Matsubara H, Kizima K, Mori Y, Murasawa S, Maruya;ma K, Inada M, Iwasaka T, Masaki H, Ohkubo N. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from falling myopathic hearts and inhibit cell growth and collagen metabolism (abstract). Circulation 1997;96 (Suppl):I-477.
93. Kawano H, Do YS, Yang DC, Chan T, Kawana Y, Barr M, Starnes VA, Hsueh WA. All effects in human cardiac fibroblasts (abstract). Circulation 1997;96 (Suppl):I-629.
94. Nickenig G, Vetter H, Geisen G, Sachinidis A. Are there more than two angiotensin receptor subtypes? (Abstract.) Circulation 1997:96 (Suppl):I-613.
95. Lee YM, Peng YY, Ding YA, Yen MH. Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am J Hypertens 1997;10:852-858.
96. Mukawa H, Toki Y, Shimauchi A, Okumura K, Ito K. Possible involvement of angiotensin II type 2 receptor in antihypertrophic effects exerted by the type I receptor antagonist in hypertensive rats. Eur Heart J 1997;18 (Suppl):445.
97. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 1993;324:35-42.
98. Mombouli JV, Vanhoutte PM. Kinins and endothelia control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995;35:679-705.
99. Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin-(107) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 1997;30:217-221.
100. Fernandez LA, Caride VJ, Stromberg C, Naveri L, Wicke JD. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994;24:937-940.
101. Pitt B, Chang P, Grossman W, Dunlay M, Timmermans PBMWWM. Rationale, background, and design of the randomized angiotensin receptor antagonist angiotensin-converting enzyme inhibitor study (RAAS). Am J Cardiol 1996 78:1129-1131.
102. Pitt B, Dickstein K, Benedict CR, Packer R, Willenheimer R, Murali S, Dunlay MC, Change PI, Grossman W for the RAAS Investigators. The randomized angiotensin receptor antagonists - ACE Inhibitor Study (RAAS) - Pilot Study (abstract). Circulation 1996;94:I-428.
103. Baruch L, Anand IS, Judd DL, Cohn JN, for Valsartan Study Group. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure (abstract). Circulation 1996;94:I-428.
104. Hamroff G, Blaufarb I, Mancini D, Katz S, Demopoulos L, Bijou R, Jondeau G, Olivari MT, Thomas S, LeJemtel TH. Angiotensin II receptor blockade further reduces afterload safely in patients maximally treated with ACE-inhibitors for heart failure (abstract). Circulation 1996;94:I-428.
105. Spinale FG, DeGaspara M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach S, Mukherjee R, Iannin JP, O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-2396.
106. Spinale FG, Mukherjee R, Iannin JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB, deGaspara M. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processes. Circulation 1997;96:2397-2406.
107. Richer-Giudicelli C, Fornes P, Cazaubon C, Nisato D, Recherche S, Guidicell JF. Effects of angiotensin II AT1 receptor blockade on survival, systemic and coronary hemodynamics and cardiac remodeling in post-ischemic heart failure in rats (abstract). Circulation 1997;96 (Suppl):I-644.
108. Konstam MA, Thomas I, Ramahi TM, Labresh KA, Goldman S, Lewis WR, Gradman AH, Self KS, Bittner VA, Rand WH, Kinan DJ, Smith JJ. Effects of losartan and captopril on left ventricular volume in elderly patients with heart failure: results of the ELITE ventricular function substudy (abstract). Circulation 1997;96 (Suppl):I-452.
109. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91 :691.
110. Fogari R, Corradi L, Preti P, Mugellini A, Poletti L, Lusardi P. Effects of losartan addition to lisinopril in hypertensives: A 24 hour Abpm study (abstract). Circulation 1997;96 (Suppl):I-599.
111. Yusuf S, Maggioni AP, Held P, Rouleau JL. Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD). (Abstract). Circulation 1997;96 (Suppl):I-452.
112. Pfister SL, Kotulock DA, Campbell WB. Vascular smooth muscle thromboxane A2 receptors mediate arachidonic acid-induced sudden death in rabbits. Hypertension 1997;29 (Ipt2):303-309.
113. Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/ prostaglandin H2 (TP) receptors. Prostaglandins 1992;44 (2):89-99.
114. Buzzard CJ, Pfister SL, Halushka PV, Campbell WB. Decrease in vascular TxA2 receptors in a subgroup of rabbits unresponsive to a TxA2 mimetic. Am J Physiol 1994;266 (6pt2):2320-2326.
115. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2 induced platelet aggregation and vascular constriction in spontaneously hypertensive rats (abstract). Circulation 1997;96 (Suppl):I-102.